UK-based company Ubiquigent has signed an exclusive license with the University of Southern Denmark for its UbiSite technology.
UbiSite will form a new component in Ubiquigent’s deubiquitylase (DUB) and ubiquitin-proteasome system (UPS) focused drug discovery platform.
UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture and further identification of protein ubiquitylation sites in cell and tissue samples.
The service can distinguish between ubiquitin and ubiquitin-like modifications, such as SUMO, Nedd8 and ISG15 on lysine residues, as well as on serine and threonine residues.
Professor Blagoy Blagoev, Academic Inventor of UbiSite Technology, University of Southern Denmark, commented: “DUBs regulate ubiquitylation, key to cellular protein homeostasis, activity, and degradation, and thereby hold huge potential as exciting new drug discovery targets. We are pleased to be licensing our UbiSite technology to Ubiquigent, a company that is strongly positioned to facilitate DUB focused drug discovery programmes and power advances in this largely unexploited field.”
